{"disease":{"id":"ms-multiple-sclerosis","name":"ms multiple sclerosis"},"drugs":{"marketed":[{"drug_id":"diroximel-fumarate","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"fingolimod-hydrochloride","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FINGOLIMOD HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"ublituximab-xiiy","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BRIUMVI","generic_name":"UBLITUXIMAB-XIIY","company_name":"TG THERAPEUTICS, INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vumerity","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vumerity","company_name":"University of Nebraska","drug_phase":"marketed","molecular_target":"Nuclear factor erythroid 2-related factor 2, Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01201356","title":"Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4125,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT02230969","title":"Plegridy Observational Program","phase":"","overall_status":"COMPLETED","enrollment_count":1208,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT04095377","title":"Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.","phase":"","overall_status":"COMPLETED","enrollment_count":875,"lead_sponsor_name":"QuantalX Neuroscience","has_results":false},{"nct_id":"NCT06251986","title":"A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04822623","title":"Imaging Evaluation of Central Nervous Autoimmune Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT07222618","title":"\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05000216","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":258,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT07483632","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":185,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07235644","title":"Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05083923","title":"A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT07087873","title":"Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT05798520","title":"A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06782724","title":"Psilocybin Therapy for Psychological Distress in Palliative Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":108,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT06999434","title":"Exploring the Utility of [18F]3F4AP for Demyelination Imaging","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT03155334","title":"Understanding Evaluation of Patient Information Sheets by User Testing Method","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Fondazione Italiana Sclerosi Multipla","has_results":false},{"nct_id":"NCT07304960","title":"Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04705610","title":"Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography","phase":"NA","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Association de Recherche Bibliographique pour les Neurosciences","has_results":false},{"nct_id":"NCT07355387","title":"Home Based Functional Balance Intervention for Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT05359653","title":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06599866","title":"Turkish Validity and Reliability of the Core Lower Urinary Tract Symptoms Questionnaire in Individuals With Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Kutahya Health Sciences University","has_results":false},{"nct_id":"NCT02097849","title":"Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05991297","title":"Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Nermin Çalışır","has_results":false},{"nct_id":"NCT06199219","title":"Ex-Plissit Model Based Counseling on Sexual Function and Sexual Satisfaction","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Necmettin Erbakan University","has_results":false},{"nct_id":"NCT03453125","title":"Improving Learning in Hispanics With TBI or MS","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Kessler Foundation","has_results":false},{"nct_id":"NCT07521384","title":"Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":36,"lead_sponsor_name":"Healing Hope International","has_results":false},{"nct_id":"NCT05857280","title":"EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)","phase":"NA","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Sheikh Shakhbout Medical City","has_results":false},{"nct_id":"NCT05912595","title":"EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Sheikh Shakhbout Medical City","has_results":false},{"nct_id":"NCT06677710","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":34,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT04602390","title":"Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Anokion SA","has_results":true},{"nct_id":"NCT04379661","title":"SUNLIGHT Study: Online Support Groups for MS to Address COVID-19","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03451175","title":"Reproductibility of Cystometry in Multiple Sclerosis Patient","phase":"","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Pierre and Marie Curie University","has_results":false},{"nct_id":"NCT07589062","title":"Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"New York University Abu Dhabi","has_results":false},{"nct_id":"NCT04528784","title":"Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"University of Limerick","has_results":false},{"nct_id":"NCT07222956","title":"A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Moein Amin","has_results":false},{"nct_id":"NCT06681623","title":"A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Neurology Center of New England P.C.","has_results":false},{"nct_id":"NCT06322342","title":"Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Reveal Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT06683612","title":"PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Contineum Therapeutics","has_results":false},{"nct_id":"NCT05435404","title":"Qualitative Study Patient & Physician Experiences Botox COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"East Kent Hospitals University NHS Foundation Trust","has_results":false},{"nct_id":"NCT04676555","title":"Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}